New Recommendations to Eliminate Racial Bias in Blood Cancer Trials by Colleen Fleiss on February 18, 2021 at 11:12 PM
New recommendations are being designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites, said researchers from Dana-Farber Cancer Institute, the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR).
Researchers from Dana-Farber Cancer Institute, the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR) are releasing recommendations designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites.
African Americans are more than twice as likely as whites to be diagnosed with multiple myeloma and to die from the blood cancer Data from large multiple.
New recommendations aim to eliminate racial bias in myeloma trials eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.